Hutchmed (HCM) said late Monday that China's National Medical Products Administration has approved its supplemental new drug application for Orpathys to treat certain adult patients with non-small cell lung cancer.

The drugmaker said the regulator also converted Orpathys' prior conditional approval for previously treated patients to full approval.

The updated label will now include both treatment-naive and previously treated patients in China, Hutchmed said.